SG11201906579UA - Pyridine derivative as ask1 inhibitor and preparation method and use thereof - Google Patents
Pyridine derivative as ask1 inhibitor and preparation method and use thereofInfo
- Publication number
- SG11201906579UA SG11201906579UA SG11201906579UA SG11201906579UA SG11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- pyridine derivative
- ask1 inhibitor
- ask1
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Pyridine Derivative as ASK1 Inhibitor and Preparation Method and Use thereof Disclosed in the present invention are a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and also disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710054224 | 2017-01-22 | ||
| PCT/CN2018/073640 WO2018133866A1 (en) | 2017-01-22 | 2018-01-22 | Pyridine derivative as ask1 inhibitor and preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906579UA true SG11201906579UA (en) | 2019-08-27 |
Family
ID=62907792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906579UA SG11201906579UA (en) | 2017-01-22 | 2018-01-22 | Pyridine derivative as ask1 inhibitor and preparation method and use thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11040968B2 (en) |
| EP (1) | EP3572412B1 (en) |
| JP (1) | JP6650552B2 (en) |
| KR (1) | KR102089234B1 (en) |
| CN (1) | CN109071538B (en) |
| AU (1) | AU2018209574B2 (en) |
| BR (1) | BR112019014756B1 (en) |
| CA (1) | CA3050346C (en) |
| DK (1) | DK3572412T3 (en) |
| EA (1) | EA037005B1 (en) |
| ES (1) | ES2870524T3 (en) |
| MX (1) | MX2019008698A (en) |
| MY (1) | MY174821A (en) |
| PH (1) | PH12019501688A1 (en) |
| PL (1) | PL3572412T3 (en) |
| SG (1) | SG11201906579UA (en) |
| WO (1) | WO2018133866A1 (en) |
| ZA (1) | ZA201904737B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201833108A (en) * | 2017-03-03 | 2018-09-16 | 大陸商江蘇豪森藥業集團有限公司 | Amide derivatives inhibitors, preparation methods and uses thereof |
| JOP20190221A1 (en) | 2017-04-05 | 2019-09-23 | Seal Rock Therapeutics Inc | Ask1 inhibitor compounds and uses thereof |
| IL270525B2 (en) | 2017-05-12 | 2024-06-01 | Enanta Pharm Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10246439B2 (en) | 2017-05-25 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218051A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2019034096A1 (en) * | 2017-08-17 | 2019-02-21 | Sunshine Lake Pharma Co., Ltd. | Fused bicyclic compounds and uses thereof in medicine |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
| KR20210005195A (en) | 2018-05-02 | 2021-01-13 | 이난타 파마슈티칼스, 인코포레이티드 | Tetrazole comprising an apoptosis signal modulating kinase 1 inhibitor and methods of use thereof |
| US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| JP7096460B2 (en) * | 2018-07-20 | 2022-07-06 | 福建▲広▼生中霖生物科技有限公司 | Crystal form as an ASK1 inhibitor, its production method and utilization |
| CN111107848B (en) * | 2018-08-10 | 2023-05-23 | 江苏豪森药业集团有限公司 | Pharmaceutical composition containing amide derivatives, and preparation method and application thereof |
| TW202021967A (en) * | 2018-08-14 | 2020-06-16 | 大陸商江蘇豪森藥業集團有限公司 | Salts of apoptosis signal-regulating kinase 1 inhibitors and crystalline forms thereof |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN110922407B (en) * | 2018-09-19 | 2021-11-12 | 广东东阳光药业有限公司 | Crystal forms of benzoylaminopyridine derivatives and uses thereof |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| KR20210118891A (en) * | 2019-01-24 | 2021-10-01 | 지앙수 아오사이캉 파마수티칼 씨오., 엘티디. | 5-(4-pyridyloxy)pyrazole compounds as TGF-β R1 kinase inhibitors |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN110577534B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
| CN110577538B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
| CN110577541B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
| CN110577533B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
| CN110577535B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
| CN110577539B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
| CN110577537B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
| CN110577540B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
| CN110577536B (en) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | Salts of benzoylaminopyridine derivatives and their use in medicine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI625121B (en) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | Apoptosis signal-regulating kinase inhibitors |
| UY34573A (en) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | QUINASE INHIBITOR REGULATING THE APOPTOSIS SIGNAL |
| CN103570625A (en) * | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-aryl-heteroaryl)-4-aryl-aryl carboxamide and analog as hedgehog pathway inhibitors and application thereof |
| MD4658B1 (en) * | 2013-12-20 | 2019-11-30 | Gilead Sciences Inc | Apotosis signal-regulating kinase inhibitors |
-
2018
- 2018-01-22 DK DK18741136.8T patent/DK3572412T3/en active
- 2018-01-22 MX MX2019008698A patent/MX2019008698A/en active IP Right Grant
- 2018-01-22 MY MYPI2019004120A patent/MY174821A/en unknown
- 2018-01-22 EA EA201991693A patent/EA037005B1/en unknown
- 2018-01-22 SG SG11201906579UA patent/SG11201906579UA/en unknown
- 2018-01-22 BR BR112019014756-0A patent/BR112019014756B1/en active IP Right Grant
- 2018-01-22 US US16/478,132 patent/US11040968B2/en active Active
- 2018-01-22 JP JP2019539988A patent/JP6650552B2/en active Active
- 2018-01-22 AU AU2018209574A patent/AU2018209574B2/en active Active
- 2018-01-22 CN CN201880001401.5A patent/CN109071538B/en active Active
- 2018-01-22 CA CA3050346A patent/CA3050346C/en active Active
- 2018-01-22 ES ES18741136T patent/ES2870524T3/en active Active
- 2018-01-22 WO PCT/CN2018/073640 patent/WO2018133866A1/en active Application Filing
- 2018-01-22 PL PL18741136T patent/PL3572412T3/en unknown
- 2018-01-22 KR KR1020197022629A patent/KR102089234B1/en active IP Right Grant
- 2018-01-22 EP EP18741136.8A patent/EP3572412B1/en active Active
-
2019
- 2019-07-18 ZA ZA2019/04737A patent/ZA201904737B/en unknown
- 2019-07-22 PH PH12019501688A patent/PH12019501688A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019014756B1 (en) | 2021-08-10 |
| EP3572412A1 (en) | 2019-11-27 |
| US11040968B2 (en) | 2021-06-22 |
| ZA201904737B (en) | 2020-05-27 |
| EA201991693A1 (en) | 2019-12-30 |
| JP6650552B2 (en) | 2020-02-19 |
| DK3572412T3 (en) | 2021-05-25 |
| JP2020504166A (en) | 2020-02-06 |
| PL3572412T3 (en) | 2021-09-27 |
| EP3572412A4 (en) | 2019-11-27 |
| CA3050346C (en) | 2020-07-14 |
| MY174821A (en) | 2020-05-18 |
| EA037005B1 (en) | 2021-01-26 |
| BR112019014756A2 (en) | 2020-03-03 |
| CN109071538A (en) | 2018-12-21 |
| KR102089234B1 (en) | 2020-05-15 |
| ES2870524T3 (en) | 2021-10-27 |
| CN109071538B (en) | 2020-03-17 |
| PH12019501688A1 (en) | 2020-03-09 |
| AU2018209574B2 (en) | 2021-04-08 |
| CA3050346A1 (en) | 2018-07-26 |
| WO2018133866A1 (en) | 2018-07-26 |
| EP3572412B1 (en) | 2021-03-03 |
| AU2018209574A1 (en) | 2019-09-05 |
| US20200031823A1 (en) | 2020-01-30 |
| KR20190110103A (en) | 2019-09-27 |
| MX2019008698A (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501688A1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
| PH12018550120A1 (en) | Steroid derivative fxr agonist | |
| MX2023001876A (en) | Rapamycin derivatives. | |
| MX2018001491A (en) | Methods for preparation of bile acids and derivatives thereof. | |
| MX2017013797A (en) | Janus kinase inhibitor. | |
| PH12019500480A1 (en) | Pyridine compound | |
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| SA519402288B1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2023004309A (en) | Imidazole-containing inhibitors of alk2 kinase. | |
| MX2020002696A (en) | Bisamide sarcomere activating compounds and uses thereof. | |
| PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
| MX2021006544A (en) | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer. | |
| SA520411635B1 (en) | Fused Ring Derivative as A2A Receptor Inhibitor | |
| MX2017000208A (en) | Quinolizinone derivatives as pi3k inhibitors. | |
| PH12016502246B1 (en) | Carboxamide derivatives | |
| MX2021007247A (en) | Rapamycin derivatives. | |
| MX2019003317A (en) | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors. | |
| PH12019550154A1 (en) | Azetidine derivative | |
| PH12020550649A1 (en) | Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds | |
| TN2019000038A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| MY180727A (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease | |
| PH12021550572A1 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof |